MY 1
Alternative Names: CCRIS 4212; MS-5101; My-1; Mycobacterium bovis bcg extract; SelfenonLatest Information Update: 22 Jan 2007
At a glance
- Originator Nihon Schering
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Lymphoma; Malignant melanoma
Most Recent Events
- 22 Jan 2007 Discontinued - Preregistration for Cancer in Japan (Injection)
- 22 Jan 2007 Discontinued - Preregistration for Lymphoma in Japan (Injection)
- 22 Jan 2007 Discontinued - Preregistration for Malignant melanoma in Japan (Injection)